Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

paclitaxel

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

- PMLiVE

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Hopes to catch up with rivals in the market

- PMLiVE

Lilly boosted by survival data for key growth drug Verzenio

Chases Pfizer's Ibrance

Celgene building

Triplet approvals for myeloma boost Celgene in Q2

Surge in approvals and pipeline as merger nears

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

- PMLiVE

Celgene cuts back Jounce alliance ahead of BMS merger

Next-gen immuno-oncology alliance lives on

- PMLiVE

Otezla scores new indication as speculation over potential buyers grows

Who will buy blockbuster psoriasis drug?

- PMLiVE

Von der Leyen elected new European Commission president

Pledges green deal and universal healthcare for 500m citizens

- PMLiVE

FDA fast-tracks Jardiance for heart failure review

Would challenge Novartis' Entresto

Bristol Myers Squibb logo

Faced with regulator’s merger concerns, BMS want to offload Otezla

Sell-off will mean merger delay

- PMLiVE

Celgene says no to Mereo’s cancer drug etigilimab

UK biotech will focus on rare disease drugs

- PMLiVE

Lilly claims cluster headache first for CGRP drug Emgality

Competition fierce in new class

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links